the DBL report

Issue #137, March 2024

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on January 16, 2024. The Committee reviewed Manufacturer submissions for fourteen (14) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of fifteen (15) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, twenty-two (22) Drug Products and Devices underwent Expedited Review for listing on the *ADBL* effective March 1, 2024.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.php

Highlights of Products Originally Reviewed by the Canadian Agency for Drugs and Technologies in Health (CADTH)

The following Drug Products were reviewed by CADTH and the Expert Committee and added to the *ADBL* effective March 1, 2024:

- **BIJUVA 1 mg/100 mg capsule** (estradiol hemihydrate/ progesterone) (KTI)
- **EMPAVELI* 1080 mg/20 mL (54 mg/mL) vial injection** (pegcetacoplan) (BVM) via Special Authorization (SA) for the indication of Paroxysmal Nocturnal Hemoglobinuria (PNH)
- **SKYRIZI* 360 mg/dose injection cartridge & 600 mg/10 mL vial injection** (risankizumab) (ABV) via SA

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.php.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (03/2024)

for the indication of Moderately to Severely Active Crohn's Disease

- **ULTOMIRIS* 100 mg/mL (1100 mg/11 mL & 300 mg/3 mL) and 10 mg/mL injections** (ravulizumab) (APG) via SA for the indications of PNH & atypical Hemolytic Uremic Syndrome (aHUS)
- **XOLAIR* 75 mg/0.5 mL injection syringe** (omalizumab) (NOV) via SA for the indication of Asthma
- **XOLAIR* 150 mg/mL injection syringe** (omalizumab) (NOV) via SA for the indications of Chronic Idiopathic Urticaria (CIU) and Asthma

Highlights of Drug Products Added

The following Drug Products were reviewed by the Expert Committee and added to the *ADBL* effective March 1, 2024:

- **PRZ-METFORMIN 1000 mg tablet** (metformin hydrochloride) (PCI)
- **TREMFYA ONE-PRESS* 100 mg/1 mL auto-injector syringe** (guselkumab) (JAI) via SA for the indication of Plaque Psoriasis

Highlights of Changes to Currently Listed Products

The benefit listing status of the following Drug Products have been changed from Restricted or Step Therapy/Special Authorization Benefits to a Regular Benefit effective March 1, 2024:

- **RIVAROXABAN 2.5 mg, 10 mg, 15 mg & 20 mg tablets** (various brands: APX, BAI, PMS, DRL, SDZ, SIV & TAR)
- **TEVA-RIVAROXABAN 10 mg, 15 mg & 20 mg tablets** (rivaroxaban) (TEV)

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Products to the *ADBL* has resulted in the creation of New IC Groupings, effective March 1, 2024:

- **TARO-PERAMPANEL* 2 mg, 4 mg, 6 mg, 8 mg, 10 mg & 12 mg tablets** (perampanel) (TAR) via SA

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).

ABC 81171 (03/2024)